Heartflow (NASDAQ:HTFL) Trading 6.5% Higher – Time to Buy?

Heartflow, Inc. (NASDAQ:HTFL)’s share price rose 6.5% during trading on Tuesday . The company traded as high as $44.32 and last traded at $44.6610. Approximately 1,241,238 shares traded hands during mid-day trading, a decline of 17% from the average session volume of 1,490,980 shares. The stock had previously closed at $41.94.

Analyst Ratings Changes

Several research analysts have commented on the company. Piper Sandler reaffirmed an “overweight” rating and issued a $45.00 price target (up from $38.00) on shares of Heartflow in a research report on Friday. Wells Fargo & Company increased their price objective on Heartflow from $37.00 to $39.00 and gave the company an “overweight” rating in a research report on Friday. Robert W. Baird set a $45.00 target price on shares of Heartflow in a research report on Friday. Benchmark reiterated a “buy” rating on shares of Heartflow in a research note on Friday. Finally, Weiss Ratings upgraded shares of Heartflow from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $43.43.

Heartflow Stock Up 6.4%

The firm has a 50-day moving average of $29.35 and a 200 day moving average of $27.85. The stock has a market capitalization of $3.85 billion and a P/E ratio of -24.39.

Heartflow (NASDAQ:HTFL) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.15. Heartflow had a negative net margin of 55.82% and a negative return on equity of 23.50%. The company had revenue of $64.08 million during the quarter. The firm’s revenue for the quarter was up 47.7% on a year-over-year basis. Analysts predict that Heartflow, Inc. will post -0.82 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO John C.M. Farquhar sold 22,562 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $28.31, for a total value of $638,730.22. Following the completion of the transaction, the chief executive officer directly owned 436,280 shares of the company’s stock, valued at approximately $12,351,086.80. This represents a 4.92% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 106,586 shares of company stock worth $3,269,343 over the last 90 days. 7.70% of the stock is currently owned by insiders.

Institutional Trading of Heartflow

A number of large investors have recently bought and sold shares of the stock. XXEC Inc. bought a new position in shares of Heartflow during the second quarter valued at $2,524,764,000. Wellington Management Group LLP increased its position in shares of Heartflow by 20.8% during the 4th quarter. Wellington Management Group LLP now owns 5,894,070 shares of the company’s stock worth $171,812,000 after purchasing an additional 1,014,006 shares in the last quarter. BlackRock Inc. bought a new position in Heartflow during the 2nd quarter valued at about $152,502,000. Bamco Inc. NY acquired a new position in Heartflow in the second quarter valued at about $94,625,000. Finally, Jupiter Topco LLC bought a new stake in Heartflow during the second quarter worth about $70,983,000.

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.